You can buy or sell MEI Pharma and other stocks, options, ETFs, and crypto commission-free!
MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Read More Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Stock Price, News, & Analysis for MEI Pharma
MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocyti...
Simply Wall StFeb 22
What Kind Of Investor Owns Most Of MEI Pharma, Inc. (NASDAQ:MEIP)?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! A look at the shareholders of MEI Pharma, Inc. (NASDAQ:MEIP) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, ‘Don’t tell me what you think, tell me what you have in your...
Expected May 8, After Hours